Swiss pharmaceutical company Novartis AG is developing a pill containing an embedded microchip, which it hopes to submit for regulatory approval in Europe within 18 months.
The chip is activated by stomach acid and transmits information to a patch attached to the patient’s skin, which then sends it on to a doctor via the Internet or a smartphone.
